News & Events

What’s new with DiaSorin Molecular and our upcoming conferences


DiaSorin Molecular CE Marks their new Simplexa™ COVID-19 & Flu A/B Direct Assay for Detection and Differentiation of SARS-CoV-2 and Influenza in One Test.

Cypress, Calif. (September 20, 2021) – DiaSorin Molecular LLC announced today that it has CE marked its Simplexa™ COVID-19 & Flu A/B Direct kit. The multiplex test allows for the in vitro qualitative detection and differentiation of nucleic acid from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),…

DiaSorin Announces Completion of the Acquisition of Luminex Corporation

Saluggia, July 14, 2021 – DiaSorin S.p.A. (“DiaSorin”; FTSE MIB: DIA) announces it has completed the acquisition of Luminex Corporation (“Luminex”; NASDAQ: LMNX) for a price of USD 37.00 per share that corresponds to a total equity value of approximately USD 1.8 billion….

DiaSorin Molecular Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2, including the India B.1.617

Cypress, Calif. (May 21, 2021) – DiaSorin Molecular LLC announced today that it has released the Simplexa™ SARS-CoV-2 Variants Direct assay (RUO) to enable detection and discrimination of four SARS-CoV-2 mutations associated with circulating virus variants without requiring upfront RNA extraction….

Upcoming Events

Event center

DiaSorin Molecular Event Center provides high quality Continuing Education programs for laboratory professionals. Our Web-based educational seminars are designed to present current, relevant information on a number of infectious disease and other related topics. Speakers are selected for their expertise in laboratory diagnostics and excellent presentation skills.